Skip to main content
GB

GeneSys Bio

GeneSys Bio provides a portable, sample‑to‑result molecular diagnostic platform that delivers laboratory‑grade sensitivity and specificity for infectious disease testing in under an hour. The system combines proprietary genetic detection chemistry with AI‑driven analysis to produce automated, gold‑standard results on‑site, supporting modular assays for human, animal, and environmental pathogens, including antibiotic‑resistance markers.

Montefiascone, ItalyFounded 20235200+ followers
Updated 2 months ago

Funding

$107.1K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Current infectious disease diagnostics fall into three categories: rapid but low‑precision strip tests, highly accurate laboratory cultures that are slow, and accurate genetic tests that require expensive, fixed lab equipment. This trade‑off forces clinicians to choose between speed, accuracy, portability, and cost, limiting timely decision‑making and broad access to reliable testing.

Solution

GeneSys Bio offers a sample‑to‑result molecular diagnostic platform that delivers laboratory‑grade sensitivity and specificity in under one hour. The system integrates proprietary genetic detection chemistry with AI‑driven data analysis to provide gold‑standard results at the point of care. Its compact, battery‑operated design enables use in clinics, field settings, veterinary practices, and environmental monitoring sites without the need for a dedicated laboratory. The platform supports a modular assay portfolio covering human, animal, and environmental pathogens, including antibiotic‑resistance markers, allowing rapid, targeted interventions.

Target Audience

Primary customers are point‑of‑care clinicians, field health workers, veterinary practitioners, and environmental surveillance teams that need rapid, accurate infectious disease testing without laboratory facilities.

Features

  • Sample‑to‑result workflow that produces definitive results in < 60 minutes
  • High‑sensitivity, high‑specificity genetic detection comparable to laboratory gold standards
  • Integrated AI algorithms for automated result interpretation and reporting
  • Portable, battery‑powered hardware suitable for on‑site testing in diverse environments
  • Modular assay library covering human, animal, and environmental pathogens, including resistance profiling
  • Cost‑effective consumables and optimized processes that reduce per‑test expense
  • User‑friendly interface requiring minimal training and no specialized lab infrastructure
This profile is AI-generated and may contain inaccuracies.